Wide Ranks

GNLX

Genelux Corporation

2.69

Top Statistics
Market Cap 92 M Forward PE -2.20 Revenue Growth 0.00 %
Current Ratio 6.01 Trailing PE 0.0000 Earnings Growth 0.00 %
Profit Margins 0.00 % Peg Ratio Dividend Yield 0.00 %
Enterprice / EBITA -1.82 Enterprise / Revenue 6131.51 Price To Sales Trailing12 Months 11613.47
Profitability
Profit Margins 0.00 % Operating Margins -341437.50 %
Balance Sheet
Total Cash 33 M Total Cash Per Share 0.9860 Total Debt 2 M
Total Debt To Equity 5.86 Current Ratio 6.01 Book Value Per Share 0.7390
All Measures
Short Ratio 890.00 % Message Board Id finmb_11172383 Shares Short Prior Month 1 M
Return On Equity -0.8857 City Westlake Village Uuid 818a2610-5027-31af-b56b-57304f2478db
Previous Close 2.49 First Trade Date Epoch Utc 1 B Book Value 0.7390
Total Debt 2 M Volume 286421 Price To Book 3.64
Fifty Two Week Low 1.60 Total Cash Per Share 0.9860 Total Revenue 8000
Shares Short Previous Month Date 1 B Target Median Price 19.00 Audit Risk 8
Max Age 86400 Recommendation Mean 1.40 Sand P52 Week Change 0.3133
Operating Margins -341437.50 % Target Mean Price 18.40 Net Income To Common -26538000
Short Percent Of Float 0.0492 Implied Shares Outstanding 34 M Trailing Peg Ratio None
Last Fiscal Year End 1 B Average Daily Volume10 Day 266190 Average Volume10days 266190
Total Cash 33 M Next Fiscal Year End 1 B Held Percent Insiders 0.1628
Trailing PE 0.0000 Date Short Interest 1 B Most Recent Quarter 1 B
Share Holder Rights Risk 8 Regular Market Previous Close 2.49 Target Low Price 8.00
Gmt Off Set Milliseconds -18000000 Fifty Day Average 2.65 Open 2.54
Free Cashflow -11902625 State CA Dividend Yield 0.00 %
Return On Assets -0.4461 Time Zone Short Name EST Board Risk 8
Trailing Eps -0.9400 Day Low 2.48 Address1 2625 Townsgate Road
Shares Outstanding 34 M Compensation Risk 9 Price Hint 4
Target High Price 30.00 Website https://www.genelux.com 52 Week Change -0.7739
Average Volume 180173 Forward Eps -0.9400 Recommendation Key strong_buy
Compensation As Of Epoch Date 1 B Quick Ratio 579.60 % Is_sp_500 False
Regular Market Day High 2.70 Profit Margins 0.00 % Debt To Equity 5.86
Fifty Two Week High 16.60 Day High 2.70 Shares Short 1 M
Regular Market Open 2.54 Industry Key biotechnology Earnings Growth 0.00 %
Enterprise To Revenue 6131.51 Revenue Growth 0.00 % Shares Percent Shares Out 0.0415
Operating Cashflow -21445000 Currency USD Time Zone Full Name America/New_York
Market Cap 92 M Is_nasdaq_100 False Zip 91361
Quote Type EQUITY Industry Biotechnology Long Name Genelux Corporation
Overall Risk 9 Regular Market Day Low 2.48 Held Percent Institutions 0.1570
Current Price 2.69 Address2 Suite 230 Enterprise To Ebitda -1.82
Financial Currency USD Current Ratio 6.01 Gross Margins 100.00 %
Industry Disp Biotechnology Number Of Analyst Opinions 5 Country United States
Float Shares 25 M Two Hundred Day Average 3.40 Governance Epoch Date 1 B
Enterprise Value 49 M Price To Sales Trailing12 Months 11613.47 Forward PE -2.20
Regular Market Volume 286421 Ebitda -26965000 Exchange NCM
Go to Yahoo Finance Go to Seeking Alpha 
Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types.

Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer.

The company is also developing V2ACT Immunotherapy for treating pancreatic cancer.

Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate.

The company was incorporated in 2001 and is headquartered in Westlake Village, California.